Bariatric metabolic surgery (BMS) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent two prominent therapeutic approaches for obesity and its cardiovascular complications [4,5]. This evidence concerns the gene GLP1R and obesity disorder.